The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment nave or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).
|Clinical Study Identifier||NCT04062448|
|Sponsor||Janssen Pharmaceutical K.K.|
|Last Modified on||22 November 2020|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.